Karin Eastham has served on our board since September 2019. Ms. Eastham has over 35 years of experience in financial and operations management, primarily in life sciences companies. Ms. Eastham serves as a director for 3 additional public biotechnology companies, Nektar Therapeutics, Geron Corporation, and Veracyte, Inc. Her former public directorships include Illumina, Inc., MorphoSys [...]
Biomarker Challenge #2: Analysis of Complex Data More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXTTM platform investigates key [...]
Challenge #1: Comprehensive Biology from a Limited & Difficult Sample More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXTTM [...]
Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, optimizing technologies for identifying neoepitopes that are more likely to provoke an immune response remains an important [...]
A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling. We believe this [...]
2019 AACR: T-cell receptor repertoire profiling using an augmented transcriptome Immunotherapy is growing as one of the most promising therapeutic approaches in clinical oncology practice. This brings with it an increasing need for comprehensive immuno-genomic profiling of tumors to better understand the interaction with the immune system. This includes profiling of the T and [...]
2019 AACR: Development and validation of an accurate exome-scale cfDNA detection platform Neoantigens are increasingly used as biomarkers for response to checkpoint blockade therapy and as therapeutic targets for neoantigen-based personalized cancer vaccines. Accurate identification of neoantigens requires comprehensive exome and transcriptome sequencing of both a tumor biopsy and a matched normal sample to [...]
Sensitive detection of oncoviruses integrated into a comprehensive tumor immuno-genomics platform HPV, HBV, HCV and EBV viruses are causally linked to over 11% of cancers worldwide while KSHV, HTLV and MCV are linked to an additional 1%. As use of immunotherapy expands to a broader variety of cancers, it is important to understand how [...]
Aaron Tachibana joined Personalis as Chief Financial Officer in March 2019, with more than fifteen years of executive financial management experience at large, medium, and small cap public and private companies. Prior to Personalis, Mr. Tachibana was Chief Financial Officer at Lumentum from August 2015 to September 2018. Lumentum is a publicly listed optical and [...]
RepertoireID An analytical module of the ImmunoID NeXT Platform Comprehensive Profiling of the TCR Repertoire RepertoireID, an analytics module of the ImmunoID NeXT Platform, enables the detection and analysis of the top TCRα and TCRβ clonotypes in the TCR repertoire found in the tumor microenvironment (TME) of patients’ tumors. [...]
